News & Events about Iovance Biotherapeutics Inc.
Iovance Biotherapeutics (NASDAQ:IOVA Get Rating) had its price target hoisted by analysts at Truist Financial from $16.00 to $17.00 in a report issued on Tuesday, The Fly reports. The firm currently has a buy rating on the biotechnology companys stock. Truist Financial&#...
23 January 2023 Clinigen divests Proleukin to Iovance Biotherapeutics for 166.7 million The deal includes a 41.7 million milestone payment and double-digit Proleukin global sales royalties Clinigen Limited (Clinigen) (the Company), the global pharmaceutical services company, has entered into an ...
Acquisition of Worldwide Rights to Proleukin Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in Anti-PD...
Thinking about buying stock in Iovance Biotherapeutics, Bilibili, Dada Nexus, Xpeng, or GDS Holdings? Thinking about buying stock in Iovance Biotherapeutics, Bilibili, Dada Nexus, Xpeng, or GDS Holdings? PR Newswire NEW YORK, Dec. 5, 2022 NEW YORK, Dec. 5, 2022 /PRNewswire...
Market News Video
2 months ago
In trading on Friday, shares of Iovance Biotherapeutics Inc (IOVA) touched a new 52-week low of 5.42/share. Thats a 15.18 share price drop, or -73.69% decline from the 52-week high of 20.60 set back on 12/28/2021...